Double-Blind, Placebo-Controlled, Randomized Phase 2 Study of the Proapoptotic Agent AT-101 Plus Docetaxel, in Second-Line Non-small Cell Lung Cancer

Chipuk, 2010, The BCL-2 family reunion, Mol Cell, 37, 299, 10.1016/j.molcel.2010.01.025 Lomonosova, 2008, BH3-only proteins in apoptosis and beyond: an overview, Oncogene, 27, S2, 10.1038/onc.2009.39 Adams, 2007, The Bcl-2 apoptotic switch in cancer development and therapy, Oncogene, 26, 1324, 10.1038/sj.onc.1210220 Letai, 2003, BH3 domains as BCL-2 inhibitors: prototype cancer therapeutics, Expert Opin Biol Ther, 3, 293, 10.1517/14712598.3.2.293 Kang, 2009, Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy, Clin Cancer Res, 15, 1126, 10.1158/1078-0432.CCR-08-0144 Zietlin, 2006, Antiangiogenic effect of TW37, a small-molecule inhibitor of Bcl-2, Cancer Res, 66, 8698, 10.1158/0008-5472.CAN-05-3691 Zietlin, 2008, Expanding circle of inhibition: small-molecule inhibitors of Bcl-2 as anticancer cell and antiangiogenic agents, J Clin Oncol, 26, 4180, 10.1200/JCO.2007.15.7693 MacVicar, 2009, An open-label, multicenter, phase I/II study of AT-101 in combination with docetaxel (D) and prednisone (P) in men with hormone refractory prostate cancer (HRPC), J Clin Oncol, 27, 15s, 10.1200/jco.2009.27.15_suppl.5062 Shepherd, 2000, Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy, J Clin Oncol, 18, 2095, 10.1200/JCO.2000.18.10.2095 Fossella, 2000, Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group, J Clin Oncol, 18, 2354, 10.1200/JCO.2000.18.12.2354 Hanna, 2004, Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy, J Clin Oncol, 22, 1589, 10.1200/JCO.2004.08.163 Therasse, 2000, New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada, J Natl Cancer Inst, 92, 205, 10.1093/jnci/92.3.205 Chang, 2009, A genomic strategy to elucidate modules of oncogenic pathway signaling networks, Mol Cell, 34, 104, 10.1016/j.molcel.2009.02.030 Bild, 2006, Oncogenic pathway signatures in human cancers as a guide to targeted therapies, Nature, 439, 353, 10.1038/nature04296 Bild, 2006, Linking oncogenic pathways with therapeutic opportunities, Nat Rev Cancer, 6, 735, 10.1038/nrc1976